Strategies to Encourage the Adoption of Biosimilars
Here are three ways plan sponsors can promote and manage the appropriate use of biosimilars to improve drug affordability and access for members.
Read MoreReducing the Unexpected and Unnecessary Costs of Musculoskeletal Condition Care
Musculoskeletal (MSK) injuries or disorders affect nearly half of U.S. adults1 and are one of the top health categories of plan sponsor spend at $420B. This topic was the focus of a breakout sessi...
Read MoreWhat Is Drug Trend and How to Manage it
Drug trend, a good annual barometer for plan sponsor who are looking to control traditional and specialty drug costs, can and should be managed to improve medication access. This topic was the foc...
Read MoreAddressing Contraceptive Care Needs
There are steps plan sponsors can take to address reproductive health care needs, beginning with contraceptive care.
Read MoreWith the right formulary, plans can control drug costs while preserving access
Each plan determines which formulary is best for its unique circumstances.
Read MoreStudy: Progression of cardiodiabesity increases care utilization and costs
The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.
Read MoreEasing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read MoreEvernorth Announces Industry-First Financial Guarantee For GLP-1 Spend
EncircleRx solution now includes financial predictability for health plan sponsors to help expand access for appropriate patients.
Read MoreClinically Speaking: Boosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read MoreUncovering behind-the-scenes challenges in bringing gene therapies to market
Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.
Read More